Literature DB >> 25249398

Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation.

Dimos D Mitsikostas1, Christina I Deligianni.   

Abstract

Nocebo affects significantly adherence and treatment outcome and varies considerably among neurological conditions. We aimed to evaluate a questionnaire to predict nocebo in outpatients seeking neurological consultation. A four-item (rating range 4-20) self-fulfilled questionnaire (Q-No) was given in outpatients seeking neurological consultation at the Athens Naval Hospital. A blind to Q-No scoring neurologist rated outpatients as nocebo or no-nocebo after follow-up of >6 months. 341 (71.5 % females) patients with mean age 46.9 (±13.8) years fulfilled the requested follow-up and Q-No. The mean total score was 13.2 (±3.7). The Crombach's alpha coefficient was 0.627. Neurologist suggested 80 patients (23.7 %) as nocebo and 258 as no-nocebo (mean Q-No score = 12.4 95 % CI [12.0-12.9] and 15.8, 95 % CI [15.1-16.6], respectively). Using a cut-off at score 15 the Q-No predicts nocebo with 71.7 % specificity, 67.5 % sensitivity and 42.5 % positive predictive value. Q-No may serve as a useful tool to predict nocebo in outpatients seeking neurological consultation.

Entities:  

Mesh:

Year:  2014        PMID: 25249398     DOI: 10.1007/s10072-014-1959-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  9 in total

Review 1.  Nocebo in headaches: implications for clinical practice and trial design.

Authors:  Dimos D Mitsikostas
Journal:  Curr Neurol Neurosci Rep       Date:  2012-04       Impact factor: 5.081

2.  Nocebo effects in multiple sclerosis trials: a meta-analysis.

Authors:  D Papadopoulos; D D Mitsikostas
Journal:  Mult Scler       Date:  2010-06-10       Impact factor: 6.312

3.  Nocebo effects, patient-clinician communication, and therapeutic outcomes.

Authors:  Luana Colloca; Damien Finniss
Journal:  JAMA       Date:  2012-02-08       Impact factor: 56.272

Review 4.  New insights into the placebo and nocebo responses.

Authors:  Paul Enck; Fabrizio Benedetti; Manfred Schedlowski
Journal:  Neuron       Date:  2008-07-31       Impact factor: 17.173

Review 5.  The placebo response: how words and rituals change the patient's brain.

Authors:  Fabrizio Benedetti; Martina Amanzio
Journal:  Patient Educ Couns       Date:  2011-05-28

6.  Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta-analysis.

Authors:  P Stathis; M Smpiliris; S Konitsiotis; D D Mitsikostas
Journal:  Eur J Neurol       Date:  2012-11-12       Impact factor: 6.089

Review 7.  The nocebo effect and its relevance for clinical practice.

Authors:  Luana Colloca; Franklin G Miller
Journal:  Psychosom Med       Date:  2011-08-23       Impact factor: 4.312

Review 8.  Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice.

Authors:  D D Mitsikostas; N G Chalarakis; L I Mantonakis; E-M Delicha; P P Sfikakis
Journal:  Eur J Neurol       Date:  2011-10-04       Impact factor: 6.089

Review 9.  The nocebo effect: patient expectations and medication side effects.

Authors:  Kate Faasse; Keith J Petrie
Journal:  Postgrad Med J       Date:  2013-07-10       Impact factor: 2.401

  9 in total
  6 in total

1.  Nocebo in Biosimilars and Generics in Neurology: A Systematic Review.

Authors:  Ioanna Spanou; Theodoros Mavridis; Dimos D Mitsikostas
Journal:  Front Pharmacol       Date:  2019-07-24       Impact factor: 5.810

2.  Erenumab for headaches in idiopathic intracranial hypertension: A prospective open-label evaluation.

Authors:  Andreas Yiangou; James L Mitchell; Claire Fisher; Julie Edwards; Vivek Vijay; Zerin Alimajstorovic; Olivia Grech; Gareth G Lavery; Susan P Mollan; Alexandra J Sinclair
Journal:  Headache       Date:  2020-12-14       Impact factor: 5.887

3.  Pain experience and mood disorders during the lockdown of the COVID-19 pandemic in the United States: an opportunistic study.

Authors:  Luana Colloca; Sharon Thomas; Margaret Yin; Nathaniel R Haycock; Yang Wang
Journal:  Pain Rep       Date:  2021-09-23

4.  COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study.

Authors:  George E Fragoulis; Vassiliki-Kalliopi Bournia; Eugenia Mavrea; Gerasimos Evangelatos; Kalliopi Fragiadaki; Anastasios Karamanakos; Eyrydiki Kravariti; Katerina Laskari; Stylianos Panopoulos; Maria Pappa; Dimos D Mitsikostas; Maria G Tektonidou; Dimitrios Vassilopoulos; Petros P Sfikakis
Journal:  Rheumatol Int       Date:  2021-11-05       Impact factor: 2.631

5.  Patients' preferences for headache acute and preventive treatment.

Authors:  Dimos D Mitsikostas; Ioanna Belesioti; Chryssa Arvaniti; Euthymia Mitropoulou; Christina Deligianni; Elina Kasioti; Theodoros Constantinidis; Manolis Dermitzakis; Michail Vikelis
Journal:  J Headache Pain       Date:  2017-10-06       Impact factor: 7.277

6.  Nocebo-Prone Behaviour in Patients with Autoimmune Rheumatic Diseases during the COVID-19 Pandemic.

Authors:  George E Fragoulis; Gerasimos Evangelatos; Aikaterini Arida; Vasiliki-Kalliopi Bournia; Kalliopi Fragiadaki; Anastasios Karamanakos; Evrydiki Kravvariti; Katerina Laskari; Stylianos Panopoulos; Maria Pappa; Dimos D Mitsikostas; Maria G Tektonidou; Petros P Sfikakis
Journal:  Mediterr J Rheumatol       Date:  2020-09-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.